Free Trial
ETR:MOR

MorphoSys (MOR) Stock Price, News & Analysis

MorphoSys logo
€67.25 0.00 (0.00%)
As of 08/20/2024

About MorphoSys Stock (ETR:MOR)

Key Stats

Today's Range
€66.70
€67.30
50-Day Range
€67.25
€67.25
52-Week Range
€14.52
€69.75
Volume
5,144 shs
Average Volume
153,687 shs
Market Capitalization
$2.53 billion
P/E Ratio
N/A
Dividend Yield
1.26%
Price Target
N/A
Consensus Rating
N/A

Company Overview

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Remove Ads
Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

MOR Stock News Headlines

DOGE Social Security bombshell?
Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.
Novartis raises sales guidance until 2028
See More Headlines

MOR Stock Analysis - Frequently Asked Questions

MorphoSys' stock was trading at €67.25 at the start of the year. Since then, MOR shares have increased by 0.0% and is now trading at €67.25.
View the best growth stocks for 2025 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), NVIDIA (NVDA), SolarEdge Technologies (SEDG), Gilead Sciences (GILD), AbbVie (ABBV) and Abbott Laboratories (ABT).

Industry, Sector and Symbol

Stock Exchange
ETR
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
ETR:MOR
CIK
N/A
Fax
N/A
Employees
730
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
322.58
P/E Growth
0.06
Net Income
$-460,809,549.78
Net Margins
-226.08%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$203.82 million
Cash Flow
€129.73 per share
Price / Cash Flow
0.52
Book Value
(€6.96) per share
Price / Book
-9.67

Miscellaneous

Free Float
N/A
Market Cap
$2.53 billion
Optionable
Not Optionable
Beta
0.66
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (ETR:MOR) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners